Compare
Fortress Biotech, Inc. vs Nuvation Bio Inc. vs Journey Medical Corp vs Rockwell Medical, Inc.
| Latest fiscal year | Fortress Biotech, Inc. FBIO | Nuvation Bio Inc. NUVB | Journey Medical Corp DERM | Rockwell Medical, Inc. RMTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $63.26M | $62.90M | $61.24M | $69.26M |
| Revenue growth (YoY) | +9.7% | +699.0% | +11.1% | -31.8% |
| Gross margin | 66.9% (computed) | n/a | 65.8% (computed) | 16.9% |
| Operating margin | -111.0% | -338.7% | -13.3% | -6.8% |
| Net margin | 10.8% | -325.3% | -18.7% | -7.7% |
| Net income | $6.82M | -$204.63M | -$11.43M | -$5.31M |
| EPS (Diluted) | -$0.07 | -$0.60 | -$0.47 | -$0.15 |
| Operating cash flow | -$65.78M | -$173.43M | -$12.44M | -$659.0K |
| Free cash flow | n/a | n/a | n/a | -$1.20M |
| Cash & equivalents | $79.38M | $164.09M | $24.09M | $10.71M |
| Total assets | $185.55M | $594.82M | $94.59M | $57.15M |
| Total liabilities | $123.36M | $289.11M | $62.74M | $20.16M |
| Shareholders' equity | $49.87M | $305.72M | $31.85M | $36.98M |
| Return on year-end equity | 13.7% | -66.9% | -35.9% | -14.4% |
| Shares outstanding | 31.36M | 337.84M | n/a | 39.41M |
Revenue, most recent five fiscal years
| Fiscal year | Fortress Biotech, Inc. | Nuvation Bio Inc. | Journey Medical Corp | Rockwell Medical, Inc. |
|---|---|---|---|---|
| Latest | $63.26M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $61.24M Ended 2025-12-31 | $69.26M Ended 2025-12-31 |
| 1 year earlier | $57.67M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $55.13M Ended 2024-12-31 | $101.49M Ended 2024-12-31 |
| 2 years earlier | $84.51M Ended 2023-12-31 | $0 Ended 2023-12-31 | $59.66M Ended 2023-12-31 | $83.61M Ended 2023-12-31 |
| 3 years earlier | $75.74M Ended 2022-12-31 | n/a | $71.00M Ended 2022-12-31 | $72.81M Ended 2022-12-31 |
| 4 years earlier | $68.79M Ended 2021-12-31 | n/a | $63.13M Ended 2021-12-31 | $61.93M Ended 2021-12-31 |